Login Register Cart 0
Generic placeholder image

Recent Advances in Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-4344
ISSN (Online): 2772-4352

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Perspective Article

Taming the Storm in the Heart: Exploring Different Therapeutic Choices Against Myocardial Inflammation in COVID-19

Author(s): Abhigyan Choudhury and Suprabhat Mukherjee*

Volume 16, Issue 2, 2021

Published on: 16 June, 2021

Page: [89 - 93] Pages: 5

DOI: 10.2174/2772434416666210616124505

Abstract

Mechanism of cardiac injury in COVID-19 is a serious problem and plays critical role in mediating the severity of the disease. However, the mechanistic insights of the induction of the inflammatory signal leading to cardiac injury was poorly understood. However, few recent studies have indicated the involvement of Toll-Like Receptors (TLRs) as the major ‘culprit’ behind eliciting the initial signal of ‘cytokine storm’. As a result, TLRs are now considered as the therapeutic targets to develop efficacious therapeutics. Herein, we present an overall summary on the mechanistic insight of cardiac injury in COVID-19 patients and the therapeutic promises of TLR-targeted therapies.

Keywords: COVID-19, TLR, cardiac injury, cytokine storm, therapeutic intervention, targeted therapy.

« Previous
Graphical Abstract

[1]
WHO. Coronavirus disease (COVID-19) pandemic. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (Accessed on: April 21, 2021).
[2]
Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol 2020; 92(10): 2105-13.
[http://dx.doi.org/10.1002/jmv.25987] [PMID: 32383269]
[3]
Unudurthi SD, Luthra P, Bose RJC, McCarthy JR, Kontaridis MI. Cardiac inflammation in COVID-19: Lessons from heart failure. Life Sci 2020; 260: 118482.
[http://dx.doi.org/10.1016/j.lfs.2020.118482] [PMID: 32971105]
[4]
Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: A review. JAMA Cardiol 2020; 5(7): 831-40.
[http://dx.doi.org/10.1001/jamacardio.2020.1286] [PMID: 32219363]
[5]
Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020; 17(5): 259-60.
[http://dx.doi.org/10.1038/s41569-020-0360-5] [PMID: 32139904]
[6]
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[7]
Wan S, Yim AP. Cytokines in myocardial injury: Impact on cardiac surgical approach. Eur J Cardiothorac Surg 1999; 16(Suppl 1): S107-11.
[http://dx.doi.org/10.1016/S1010-7940(99)00200-6]
[8]
Pulkki KJ. Cytokines and cardiomyocyte death. Ann Med 1997; 29(4): 339-43.
[http://dx.doi.org/10.3109/07853899708999358] [PMID: 9375993]
[9]
Korff S, Katus HA, Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006; 92(7): 987-93.
[http://dx.doi.org/10.1136/hrt.2005.071282] [PMID: 16775113]
[10]
Choudhury A, Das NC, Patra R, Mukherjee S. In silico analyses on the comparative sensing of SARS- CoV-2 mRNA by the intracellular TLRs of humans. J Med Virol 2021; 93(4): 2476-86.
[http://dx.doi.org/10.1002/jmv.26776] [PMID: 33404091]
[11]
Patra R, Chandra DN, Mukherjee S. Targeting human TLRs to combat COVID-19: A solution? J Med Virol 2021; 93(2): 615-7.
[http://dx.doi.org/10.1002/jmv.26387] [PMID: 32749702]
[12]
Gao W, Xiong Y, Li Q, Yang H. Inhibition of toll- like receptor signaling as a promising therapy for inflammatory diseases: A journey from molecular to nano therapeutics. Front Physiol 2017; 8: 508.
[http://dx.doi.org/10.3389/fphys.2017.00508] [PMID: 28769820]
[13]
Sherer B, Bender AT, Pereira A, Reissig S, Haselmayer P, Okitsu SL. O37 M5049, a novel potent and selective inhibitor of toll-like receptors 7 and 8 (TLR 7/8). Lupus Sci Med 2020; 7(1): A28-AA.
[http://dx.doi.org/10.1136/lupus-2020-eurolupus.48]
[14]
Hoy SM. Canakinumab: A review of its use in the management of systemic juvenile idiopathic arthritis. BioDrugs 2015; 29(2): 133-42.
[http://dx.doi.org/10.1007/s40259-015-0123-8]
[15]
Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003; 48(4): 927-34.
[http://dx.doi.org/10.1002/art.10870] [PMID: 12687534]
[16]
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol 2020; 92(7): 814-8.
[http://dx.doi.org/10.1002/jmv.25801] [PMID: 32253759]
[17]
Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study. Ann Rheum Dis 2020; 79(10): 1277-85.
[http://dx.doi.org/10.1136/annrheumdis-2020-218122] [PMID: 32620597]
[18]
Mehta P, Porter JC, Manson JJ, et al. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: Challenges and opportunities. Lancet Respir Med 2020; 8(8): 822-30.
[http://dx.doi.org/10.1016/S2213-2600(20)30267-8] [PMID: 32559419]
[19]
Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect 2020; 81(2): 318-56.
[http://dx.doi.org/10.1016/j.jinf.2020.04.017] [PMID: 32333918]
[20]
Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol 2020; 146(1): 137-146.e3.
[http://dx.doi.org/10.1016/j.jaci.2020.05.019] [PMID: 32470486]
[21]
Zhang J. Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease. J Clin Invest 2007; 117(4): 871-3.
[http://dx.doi.org/10.1172/JCI31860] [PMID: 17404615]
[22]
Magro G. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. Virus Res 2020; 286: 198070.
[http://dx.doi.org/10.1016/j.virusres.2020.198070] [PMID: 32569708]
[23]
Fallerini C, Daga S, Mantovani S, et al. Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study. Elife 2021; 10: e67569.

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy